- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07947056
A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin (PRaCTISe-HR)
A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin
This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.
연구 개요
상태
상세 설명
Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Dr PK Bhavani, MBBS., MPH., PGDBEME
- 전화번호: 044 2836 9537
- 이메일: bhavani.pk@icmr.gov.in
연구 연락처 백업
- 이름: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- 전화번호: 044 2836 9518
- 이메일: narendra.ng@icmr.gov.in
연구 장소
-
-
Andhra Pradesh
-
Guntur, Andhra Pradesh, 인도, 522503
- 모병
- All India Institute of Medical Sciences(AIIMS), Mangalagiri
-
연락하다:
- Dr S Sathiyanarayanan, MBBS., MD
- 전화번호: 08645 280021
- 이메일: sathiya@aiimsmangalagiri.edu.in
-
-
Assam
-
Guwahati, Assam, 인도, 781101
- 모집하지 않고 적극적으로
- All India Institute of Medical Sciences, Guwahati
-
-
Gujarat
-
Rajkot, Gujarat, 인도, 360001
- 아직 모집하지 않음
- Govt. PDU Medical College
-
연락하다:
- Dr Bhoomika Patel, MBBS., MD
- 전화번호: 0281 245 8337
- 이메일: doctorbhoomika@gmail.com
-
Surat, Gujarat, 인도, 395001
- 모집하지 않고 적극적으로
- Govt. Medical College and NCH
-
-
Maharashtra
-
Mumbai, Maharashtra, 인도, 400008
- 모병
- Grant Govt. Medical College & Sir JJ Group of Hospitals
-
연락하다:
- Dr Priti Meshram, MBBS., MD., DNB
- 전화번호: 022 2373 5555
- 이메일: drpritimeshram@gmail.com
-
Nagpur, Maharashtra, 인도
- 아직 모집하지 않음
- All India Institute Of Medical Sciences, Nagpur
-
연락하다:
- Dr Yogesh Bahurupi, MBBS., MD
- 전화번호: 0712 2352078
- 이메일: dr.yogeshab@gmail.com
-
-
Meghālaya
-
Shillong, Meghālaya, 인도, 793018
- 모병
- North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
-
연락하다:
- Dr Monaliza Lyngdoh, MBBS., MD
- 전화번호: 0364 2538013
- 이메일: monalizalyngdoh@gmail.com
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, 인도, 110030
- 아직 모집하지 않음
- National Institute of TB and Respiratory Diseases
-
연락하다:
- Dr Jitendra Kumar Saini, MBBS., MD
- 전화번호: 011 2651 3325
- 이메일: drsaini1973@gmail.com
-
-
Odisha
-
Bhubaneswar, Odisha, 인도, 751019
- 모집하지 않고 적극적으로
- All India Institute of Medical Sciences (AIIMS), Bhubaneswar
-
Bhubaneswar, Odisha, 인도, 751001
- 모집하지 않고 적극적으로
- Post Graduate Institute of Medical Education & Research, Capital Hospital
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, 인도, 600031
- 모병
- ICMR - National Institute for Research in Tuberculosis
-
연락하다:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
- 전화번호: 044 2836 9537
- 이메일: bhavani.pk@icmr.gov.in
-
연락하다:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- 전화번호: 044 2836 9518
- 이메일: narendra.ng@icmr.gov.in
-
수석 연구원:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
-
수석 연구원:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
-
부수사관:
- Dr R Balaji, MBBS., MD.,
-
-
Telangana
-
Hyderabad, Telangana, 인도, 500038
- 모병
- Govt. General and Chest Hospital, Osmania Medical College
-
연락하다:
- Dr V Karthik, MBBS., MD
- 전화번호: 04083814421
- 이메일: vkarthikrao19@gmail.com
-
-
Uttar Pradesh
-
Agra, Uttar Pradesh, 인도, 282002
- 모병
- Sarojini Naidu Medical College
-
연락하다:
- Dr Gajendra Vikram Singh, MBBS., MD
- 전화번호: 0562 2260353
- 이메일: drsinghgv@gmail.com
-
Allahābād, Uttar Pradesh, 인도, 211002
- 모병
- Moti Lal Nehru Medical College
-
연락하다:
- Dr Amitabh Das Shukla, MBBS., MD
- 전화번호: 0532 261 3592
- 이메일: adshukla1977@gmail.com
-
Lucknow, Uttar Pradesh, 인도, 226003
- 모병
- King George Medical University
-
연락하다:
- Dr Rajiv Garg, MBBS., MD
- 전화번호: 0522 2255167
- 이메일: rajivkgmc@gmail.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Individuals aged equal or above 14 years.
- Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
- Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
- If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
- Willing to follow the trial procedures
Exclusion Criteria:
-
Body weight less than 30 kg in adults
-
Anti-TB treatment, >14 days for the current illness
-
Known Resistance to rifampicin & Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA
-
Patients with serious forms of Extra-pulmonary TB
-
HIV Patients on second line ART regimens.
-
Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities
- ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
- Serum Creatinine >1.2 mg/dl.
-
Pregnant or lactating mothers
-
Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability
-
Patients with h/o of concomitant medications which may interfere with study drugs
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 2H R25 ZE /4 H R10 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
실험적: 2 H R25 ZE/ 4 H R25 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
실험적: 2 H R25 ZE L/2 H R25 E L
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg) Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin. |
Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs. |
|
활성 비교기: 2 H R10 ZE /4H R10 E
Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol |
Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
기간: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of patients with grade 3 or 4 adverse drug reactions.
기간: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
기간: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
기간: At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
|
|
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
기간: At 1st Month
|
At 1st Month
|
|
|
The cost effectiveness of different treatment regimens
기간: Through treatment completion, an average of 24 weeks
|
Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB. |
Through treatment completion, an average of 24 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Dr PK Bhavani, MBBS., MPH., PGDBEME, ICMR - National Institute for Research in Tuberculosis
- 수석 연구원: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,, ICMR - National Institute for Research in Tuberculosis
간행물 및 유용한 링크
일반 간행물
- Kannabiran BP, Arthanari J, Bhaskar A, Narayanan MKS, Inbaraj LR. Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: A systematic review & meta-analysis. Indian J Med Res. 2025 May;161(5):449-460. doi: 10.25259/IJMR_1673_2024.
- Perumal Kannabiran B, Palaniappan NA, Manoharan T, Paramasivam PK, Saini JK, Ansari MS, Jayabal L, Aggarwal AN, Garg R, Subramanyam B, Thakur D, Pantula S, P M R, Gs V, Natarajan S, Ammayappan RK, Manpreet B, Ganesan M, Angamuthu D, Chinnaiyan P, Singh M, Chandrasekaran P, Swaminathan S. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial. Open Forum Infect Dis. 2024 Feb 2;11(3):ofae034. doi: 10.1093/ofid/ofae034. eCollection 2024 Mar.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 호흡기 감염
- 감염
- 호흡기 질환
- 폐 질환
- 그람 양성 세균 감염
- 세균 감염
- 세균 감염 및 진균증
- 방선균 감염
- 마이코박테리움 감염
- 결핵
- 결핵, 폐
- 건강 관리 품질, 접근 및 평가
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 치료학
- 건강 관리 평가 메커니즘
- 건강 관리의 질
- 다 환식 화합물
- 이종 사이 클릭 화합물, 4 개 이상의 고리
- 리파 마이신
- 락탐, 마크로 사이 클릭
- 마크로 사이 클릭 화합물
- 플루오로 퀴놀론
- 4- 퀴놀론
- 퀴놀론
- 퀴놀린
- Ofloxacin
- 역학 연구 특성
- 리팜핀
- 레보플록사신
- 임상 프로토콜
기타 연구 ID 번호
- 2025 011
- CTRI/2026/02/102698 (레지스트리 식별자: CLINICAL TRIALS REGISTRY - INDIA)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .